EHA 2023 | Real-world treatment patterns in third-line therapy for R/R myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on real-world treatment patterns in patients initiating third-line therapy for relapsed/refractory (R/R) multiple myeloma. Dr Ramasamy explores the findings of a recent retrospective analysis that examined European patient data from 2016 to 2021. The study aimed to provide insights into clinical practice and identify standard-of-care practices and treatment gaps in R/R multiple myeloma management. Dr Ramasamy delves into the predominance of immunomodulatory-based regimens as third-line therapy across multiple countries and the shifting trends observed in treatment approaches. He highlights the increasing utilization of triplets and the rise in anti-CD38 monoclonal antibody use in later lines of therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So the work we did, collectively with several other groups, is to look at the third line treatments across Europe, particularly in the last ten years. So, we looked at data from a number of different countries: Germany, Italy, France, UK and Spain, and we looked at two particular timelines: before 2018 and after 2018, particularly looking at the change in the third line therapy. We pulled out data from both insurance claims as well as from clinic chart reviews from these countries...
So the work we did, collectively with several other groups, is to look at the third line treatments across Europe, particularly in the last ten years. So, we looked at data from a number of different countries: Germany, Italy, France, UK and Spain, and we looked at two particular timelines: before 2018 and after 2018, particularly looking at the change in the third line therapy. We pulled out data from both insurance claims as well as from clinic chart reviews from these countries. And what we were studying is that treatment is significantly changed between 2016 and 2018 to the more recent period. What really happened is less of retreatment is being used and more novel therapies such as daratumumab incorporation in relapse as well as pomalidomide-based therapies is coming through in the third line setting. But we still find a proportion of patients are being retreated with some of the previous agents used in their newly diagnosed or early relapse setting, again in third line. So this tells us that new therapies need to be incorporated in the third line setting to improve outcomes for patients with relapsed/refractory myeloma.
Read more...
